Ohio State is in the process of revising websites and program materials to accurately reflect compliance with the law. While this work occurs, language referencing protected class status or other activities prohibited by Ohio Senate Bill 1 may still appear in some places. However, all programs and activities are being administered in compliance with federal and state law.

Mary Kate McCulloch

Mary Kate McCulloch

Mary Kate McCulloch

Advisor: Afrooz Rashnonejad

mcculloch.68@buckeyemail.osu.edu

Nationwide Children's Hospital, Abigail Wexner Research Institute, RB4-WC3580

Areas of Expertise

  • Gene expression
  • Molecular medicine
  • Molecular neurobiology

Education

  • BS: Ohio University

MK is a PhD student focused on developing AAV-based gene therapies for rare neurodegenerative and neuromuscular diseases, with a primary focus on Charcot-Marie-Tooth disease type 1B (CMT1B). Her work involves designing therapeutics that combine RNA interference and gene replacement strategies, and testing their efficacy both in vitro and in vivo. Additionally, she is developing a CMT1B peripheral nervous system (PNS) organoid model using patient-derived induced pluripotent stem cells (iPSCs).